儿童和青少年代谢相关脂肪性肝病研究进展*

doi:10.3969/j.issn.1672-5069.2024.04.003

实用肝脏病杂志 ›› 2024, Vol. 27 ›› Issue (4): 488-491.doi: 10.3969/j.issn.1672-5069.2024.04.003

儿童和青少年代谢相关脂肪性肝病研究进展^*

柳雅立, 张晶

100069 北京市首都医科大学附属北京佑安医院肝病三科

收稿日期:2024-04-20 出版日期:2024-07-10 发布日期:2024-07-10
通讯作者: 张晶,E-mail:zjyouan@ccmu.edu.cn
作者简介:柳雅立,男,51岁,主任医师,科室副主任。研究方向主要为脂肪性肝病。E-mail:ericliudoc@ccmu.edu.cn
基金资助:
^*首都卫生发展科研专项基金资助项目(编号:2022-2Z-2187);北京市医院管理中心临床医学发展专项基金资助项目(编号:YGLX202339);北京市卫生健康委高层次公共卫生技术人才建设项目(编号:医管局03-23);北京佑安医院院内中青年人才孵育项目 (编号:BJYAYY-YN2022-21)

Child and adolescent metabolic dysfunction-associated fatty liver disease:current state of the art and perspectives

Liu Yali, Zhang Jing

Third Department of Liver Diseases, You’an Hospital, Capital Medical University, Beijing 100069, China

Received:2024-04-20 Online:2024-07-10 Published:2024-07-10

摘要/Abstract

Key words: Metabolic dysfunction-associated fatty liver disease, Metabolic dysfunction-associated steatotic liver disease, Diagnosis, Treatment, Child and adolescent

柳雅立, 张晶. 儿童和青少年代谢相关脂肪性肝病研究进展^*[J]. 实用肝脏病杂志, 2024, 27(4): 488-491.

Liu Yali, Zhang Jing. Child and adolescent metabolic dysfunction-associated fatty liver disease:current state of the art and perspectives[J]. Journal of Practical Hepatology, 2024, 27(4): 488-491.

[1] Eslam M, Alkhouri N, Vajro P, et al. Defining paediatric metabolic (dysfunction)-associated fatty liver disease: an international expert consensus statement. Lancet Gastroenterol Hepatol,2021,6(10):864-873.
[2] Abarca-Gómez L, Abdeen Z A, Hamid Z A, et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet,2017,390(10113):2627-2642.
[3] Le M, Le D, Baez T C, et al. Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons. J Hepatol,2023,79(2):287-295.
[4] Eslam M, Newsome P N, Sarin S K, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol,2020,73(1):202-209.
[5] Eslam M, Sanyal A J, George J. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology,2020,158(7):1999-2014.
[6] Kanwal F, Neuschwander-Tetri B A, Loomba R, et al. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. Hepatology,2024,79(5):1212-1219.
[7] Rinella M E, Lazarus J V, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol,2023,79(6):1542-1556.
[8] 范建高,李小英. NAFLD更名MAFLD、MASLD:背景、异同、对策. 中华肝脏病杂志,2023,28(8):789-792.
[9] Nobili V, Pinzani M. Alcoholic and non-alcoholic fatty liver in adolescents: a worrisome convergence. Alcohol Alcohol,2011,46(5):627-629.
[10] Hegarty R, Deheragoda M, Fitzpatrick E, et al. Paediatric fatty liver disease (PeFLD): All is not NAFLD - Pathophysiological insights and approach to management. J Hepatol,2018,68(6):1286-1299.
[11] 濮佳琦,王森杰,薛初晴,等. 儿童脂肪性肝病命名探析. 中华儿科杂志,2023,32(2):104-107.
[12] Zhang L, El-Shabrawi M, Baur L A, et al. An international multidisciplinary consensus on pediatric metabolic dysfunction-associated fatty liver disease. Med,2024[ahead of print] .
[13] Anderson E L, Howe L D, Fraser A, et al. Weight trajectories through infancy and childhood and risk of non-alcoholic fatty liver disease in adolescence: the ALSPAC study. J Hepatol,2014,61(3):626-632.
[14] Rupasinghe K, Hind J, Hegarty R. Updates in metabolic dysfunction-associated fatty liver disease (MAFLD) in Children. J Pediatr Gastroenterol Nutr,2023,77(5):583-591.
[15] Santoro N, Kursawe R, D'Adamo E, et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology,2010,52(4):1281-1290.
[16] Jarasvaraparn C, Vilar-Gomez E, Yates K P, et al. Age, BMI, and type 2 diabetes modify the relationship between PNPLA3 and advanced fibrosis in children and adults with NAFLD. Clin Gastroenterol Hepatol,2024,22(5):1024-1036.
[17] Walker R W, Belbin G M, Sorokin E P, et al. A common variant in PNPLA3 is associated with age at diagnosis of NAFLD in patients from a multi-ethnic biobank. J Hepatol,2020,72(6):1070-1081.
[18] Nobili V, Alisi A, Valenti L, et al. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol,2019,16(9):517-530.
[19] Oh D Y, Talukdar S, Bae E J, et al. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell,2010,142(5):687-698.
[20] Marzuillo P, Grandone A, Conte M, et al. Novel association between a nonsynonymous variant (R270H) of the G-protein-coupled receptor 120 and liver injury in children and adolescents with obesity. J Pediatr Gastroenterol Nutr,2014,59(4):472-475.
[21] Ohtani N, Kamiya T, Kawada N. Recent updates on the role of the gut-liver axis in the pathogenesis of NAFLD/NASH, HCC, and beyond. Hepatol Commun,2023,7(9):e241.
[22] 中华医学会儿科学分会内分泌遗传代谢学组,中华医学会儿科学分会消化学组,中华医学会儿科学分会青春期医学专业委员会,等. 儿童非酒精性脂肪肝病诊断与治疗专家共识. 中国实用儿科杂志,2018,33(7):487-492.
[23] Vos M B, Abrams S H, Barlow S E, et al. NASPGHAN Clinical Practice Guideline for the diagnosis and treatment of nonalcoholic fatty liver disease in children: Recommendations from the Expert Committee on NAFLD (ECON) and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN). J Pediatr Gastroenterol Nutr,2017,64(2):319-334.
[24] Di Sessa A, Guarino S, Umano G R, et al. Uric acid in pediatric MASLD definition: Is it time to implement diagnostic criteria? J Hepatol,2024,79(6):1-2.
[25] Wang C W, Huang P C, Dai C Y, et al. Comparative evaluation of pediatric fatty liver disease criteria: MASLD, ESPGHAN, NASPGHAN, and NAFLD - identifying the optimal pediatric label. J Hepatol,2024,80(4):e157-e159.
[26] Draijer L, Benninga M, Koot B. Pediatric NAFLD: an overview and recent developments in diagnostics and treatment. Expert Rev Gastroenterol Hepatol,2019,13(5):447-461.
[27] Anania C, Perla F M, Olivero F, et al. Mediterranean diet and nonalcoholic fatty liver disease. World J Gastroenterol,2018,24(19):2083-2094.
[28] Yaskolka M A, Rinott E, Tsaban G, et al. Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial. Gut,2021,70(11):2085-2095.
[29] Violi F, Cangemi R. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med,2010,363(12):1185-1186.
[30] Lavine J E, Schwimmer J B, Van Natta M L, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA,2011,305(16):1659-1668.
[31] Ji L, Dong X, Li Y, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab,2021,23(2):404-414.
[32] Weghuber D, Barrett T, Barrientos-Perez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med,2022,387(24):2245-2257.
[33] 任璐,张晓伟,刘娜. 粪菌移植治疗代谢相关脂肪性肝病的理论基础和研究进展. 中华临床营养杂志,2023,18(4):244-250.

儿童和青少年代谢相关脂肪性肝病研究进展^*

Child and adolescent metabolic dysfunction-associated fatty liver disease:current state of the art and perspectives

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	陈思彤, 卫小蝶, 韦新焕, 郭海清, 张晶. 代谢功能障碍相关脂肪性肝病诊疗进展^*[J]. 实用肝脏病杂志, 2024, 27(4): 481-483.
[2]	中华医学会肝病学分会. 代谢相关(非酒精性)脂肪性肝病防治指南(2024年版)[J]. 实用肝脏病杂志, 2024, 27(4): 494-510.
[3]	张全乐, 赵丹, 李杰, 刘三香, 刘刚, 李亚. 富马酸替诺福韦与恩替卡韦挽救治疗拉米夫定耐药的HBeAg阴性慢性乙型肝炎患者疗效分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 515-518.
[4]	薛李娜, 诸国兵, 吴琳霖, 杨小星. TAF治疗ETV经治的低病毒血症慢性乙型肝炎患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 519-522.
[5]	张丽, 陈雅雯, 盖琳, 邱红, 甄鑫, 常静霞. 乙型肝炎病毒/丙型肝炎病毒共同感染患者临床特征及其对抗病毒治疗应答反应研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 523-526.
[6]	罗洪霞, 李静秋, 李媛媛, 冯国隽, 余霞. 超重/肥胖非酒精性脂肪性肝病儿童磁共振质子密度脂肪分数检测意义研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 527-530.
[7]	任浩, 熊清芳. 多种无创检测指标预测自身免疫性肝病患者肝硬化效能比较^*[J]. 实用肝脏病杂志, 2024, 27(4): 535-538.
[8]	蒋瑶, 仲伟明, 周俏怡, 邵宁, 吕冰, 孙舒. 吗替麦考酚酯治疗难治性自身免疫性肝炎患者疗效初步研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 539-542.
[9]	柯海霞, 张娇珍, 蒙夏玲, 许政衡, 邓丕豪. 慢加急性乙型肝炎肝衰竭患者血清CRP和sTREM-1水平变化及其预测继发感染的价值研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 555-558.
[10]	赵维波, 王源, 孔令甲, 朱玉森, 岳宗柱, 商西单. 球囊压迫辅助下内镜硬化剂注射治疗乙型肝炎肝硬化并发食管静脉曲张患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 559-562.
[11]	艾孜江·艾买提, 阿布都西库尔·阿布都米吉提, 迪丽努尔·阿卜杜热合曼, 吴源泉. 骨髓间充质干细胞移植联合自拟中药治疗失代偿期肝硬化患者效果研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 567-570.
[12]	李维新, 索爱军, 王秀峰. 地佐辛联合丙泊酚靶控输注处理接受内镜下注射硬化剂治疗的乙型肝炎肝硬化并发食管静脉曲张破裂出血患者麻醉苏醒和镇痛效果研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 575-578.
[13]	汤泽宇, 顾菲, 周健文, 姜小兰, 毛雨婧, 樊琦. CT参数联合FIB-4和血清VEGF水平预测乙型肝炎肝硬化患者并发食管静脉曲张效能分析^*[J]. 实用肝脏病杂志, 2024, 27(4): 579-582.
[14]	鲍应军, 张媛, 顾俊鹏, 朱帝文, 张海潇, 曹耿飞, 阿斯哈尔·哈斯木, 任伟新. TIPSS术使用组合支架与Viatorr支架治疗肝硬化并发门静脉高压症患者长期疗效比较^*[J]. 实用肝脏病杂志, 2024, 27(4): 583-586.
[15]	夏礼鹏, 褚玉玄, 赵如盛. 增强MRI联合IVIM-DWI诊断小肝细胞癌价值研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 587-590.